Rewriting the Rules of Aging: Nexus IT Invests $60M in OneSkin’s Revolutionary Longevity Breakthrough

We are thrilled to announce a major milestone as OneSkin, the revolutionary longevity company, secures an impressive $60,000,000 in funding, marking a significant stride in transforming the landscape of skin health and aging. Founded by a visionary team of four female PhDs, OneSkin is redefining how we approach skin longevity with its breakthrough product, OS-01. This proprietary peptide is not only the first of its kind designed to reduce skin’s biological age, but it also achieves this by improving the skin barrier, supporting DNA damage repair, and preventing the accumulation of aged cells. The funds raised will empower OneSkin to accelerate research and development, ensuring that OS-01 and future innovations reach their full potential in combating age-related skin decline. By investing in cutting-edge biotechnology, the new capital will fuel clinical trials and expand production capabilities, ultimately paving the way for broad market access and enhanced patient outcomes. In tandem with an unwavering commitment to scientific excellence, OneSkin’s mission is to inspire a paradigm shift in how society perceives aging—transforming it from a relentless progression into a journey of renewal and renewal. This funding round signifies strong investor confidence and a shared belief in the company’s unique approach to skin rejuvenation and longevity. As OneSkin continues to push the boundaries of skincare science, this partnership and financial boost will undoubtedly set the stage for groundbreaking advances, further solidifying its role as a leader in the next generation of skincare innovation.